logo Click here for the Department of Medicine Home Page Click here for the UC Irvine Home Page Click here for the School of Medicine Home Page

Fellowship program 2017

Fellowship Program

The Division of Hematology/Oncology at UC Irvine's School of Medicine offers a rigorous three-year accredited fellowship program that emphasizes intensive theoretical training and a broad spectrum of clinical experience with the goal of preparing highly skilled hematologists and oncologists for careers in both clinical and academic medicine.

The division's fellowship is conducted in concert with UC Irvine's prestigious
Chao Family Comprehensive Cancer Center, one of 41 U.S. comprehensive cancer centers designated for excellence by the National Cancer Institute. The multidisciplinary cancer center at UC Irvine Medical Center is supported by more than 100 UC Irvine faculty members from five schools and 23 departments.

The division's faculty members serve patients with hematologic and oncologic disorders at the medical center, which is ranked among the top 50 U.S. hospitals by U.S. News & World Report, and at the VA Long Beach Healthcare System.
Throughout fellowship hematology/oncology fellows function as primary longitudinal caregivers to a panel of patients and serve as consultants directing the management of large numbers of patients under the supervision and guidance of faculty physicians.

The fellowship program is designed to educate and support future clinical investigators who plan to dedicate their professional careers to clinical or laboratory research in hematology and oncology. The three-year program is approved by the Accreditation Council for Graduate Medical Education (ACGME) and is recognized by the American Board of Internal Medicine (ABIM).

Clinical Training »

During the first year fellows acquire a panel of outpatients that are followed longitudinally throughout fellowship training in their continuity clinics.  Under the direct supervision of faculty members fellows receive a thorough grounding in solid tumor oncology, general hematology, and hematologic malignancies. The emphasis is on understanding the pathologic process of diseases, their clinical manifestations and complications, diagnostic methodology, evidence-based standard and experimental therapeutic modalities, clinical trials and research.

During the inpatient clinical experience fellows provide care and consultative services to a varied population of patients.  Formal teaching and attending rounds are held daily at the medical center in Orange and at the VA in Long Beach.  Teaching rounds include discussion and management of the patients, as well as didactic lectures on relevant pathophysiology and ongoing clinical trials and correlative studies. 

Fellows participate in weekly didactic lectures as well as academic activities including journal club, M&M, quality improvement, hematology conference, and disease specific lectures.  They are also encouraged to attend the 12 different disease specific tumor boards that are conducted on a weekly basis.

During hematology rotation fellows rotate through the CIBD (Center for Inherited Blood Disorders) where they learn about benign hematological conditions and hemoglobinopathies from dedicated faculty.  Bone marrow transplant and cytogenetics rotations are conducted at UCLA.

Fellows receive a thorough grounding in general hematology, hematologic malignancy and solid tumors. The emphasis is on understanding the pathologic process of diseases, the resulting functional changes, their clinical manifestations and complications, as well as diagnostic methodology, standard and experimental therapeutic modalities, clinical trials and research.

Fellows are required to undertake dedicated clinical and/or laboratory research under the supervision of a research mentor.  During the second half of the first year fellows begin exploring research options around their individual interests.  Participation in the review of clinical trial protocols through involvement in the institutional review board (IRB) is expected during the second and third year.
Research »

During the second and/or third year fellows develop and participate in a longitudinal research project spanning 12 months of protected time under the supervision of research mentor.

The University of California is a major NIH funded academic institute and offers a variety of research opportunities ranging from basic molecular biology to translational clinical trials and health outcomes are available.  Research is conducted under the supervision of the research mentor and the research oversight committee. During the research rotation fellows receive four weeks of intensive clinical hematology laboratory experience, which includes training in automated hematology, blood banking, flow cytometry, coagulation, transfusion medicine, special protein laboratory, and hemoglobin variant analysis.

Fellows are expected to develop sufficient research experience by the end of the rotation to be able to prepare papers for presentation at national and regional meetings and manuscripts for publication in peer-reviewed medical journals.

Our faculty views the successful training and ultimate career placement of the UCI hematology/oncology fellows as a fundamental responsibility, and many fellows have had highly productive research experiences.
Salary and Benefits »

The annual salary scale is:

  • First year — $60,211
  • Second year — $62,676
  • Third year — $65,005

Medical, dental and vision insurance plans are provided.

Fellows receive professional liability coverage for all activities that are part of the hematology/oncology fellowship training program. A disability plan is available through the Irvine House Staff Association. Information on specific plans is made available at the time of acceptance.

Fellows receive three weeks vacation per year. In addition, the division pays for each fellow to attend an educational conference every year and allows for educational time to attend conferences.

Eligibility »

Fellowship candidates must have completed a three-year residency program in Internal Medicine that is recognized by ACGME and the ABIM. Applicants also should be able to demonstrate their interest in the subspecialties of hematology and oncology.

Candidates must be a U.S. citizen, permanent resident, or hold a J-1 visa with ECFMG sponsorship at the time of application submission.

Candidates also must have a valid California medical license before beginning the fellowship program as required by state law. For graduates of medical schools outside the United States, please note that the licensure process can take six to 12 months or longer.

If you are not already licensed in the state, contact the Medical Board of California at 1426 Howe Ave., Suite 54, Sacramento, CA 95825-3236.

Application Process »

Fellowship candidates must have completed an ACGME-accredited Internal Medicine residency program. Applicants also must have:

  • Board-certification or board-eligibility in internal medicine
  • Proof of medical school graduation (original diploma)
  • Proof of passing the three-step United States Medical Licensing Examination® (USMLE)
  • U.S. citizenship, permanent residency, or J-1 visa with ECFMG sponsorship 

Candidates also must have a valid California medical license before beginning the fellowship program as required by state law. For graduates of medical schools outside the United States, please note that the licensure process can take six to 12 months or longer. If you are not already licensed in the state, contact the Medical Board of California online or at 1426 Howe Ave., Suite 54, Sacramento, CA 95825-3236.

Applicants with permanent residency or J-1 visas also must provide a current certificate from the Educational Commission for Foreign Medical Graduates (ECFMG) before starting the fellowship.

All applicants must apply through the Electronic Residency Application Service (ERAS), developed by the Association of American Medical Colleges to electronically transmit applications, personal statements, recommendation letters, deans' letters, transcripts and other supporting credentials from medical schools to fellowship program directors. For questions about the application process, go to ERAS online or call 215.966.3940.

Applications should be submitted as early as possible in order to meet ERAS deadlines for supporting documents and interview schedules. Late applications may not be considered.

Recent Fellow Publications »

UC Irvine Hematology/Oncology Fellowship Program
Fellows' List of Research Publications in the past 6 years: 2010-2016
(fellow names appears in BOLD type)

Management of Metastatic Colorectal Cancer in the Community-Based Setting.
Seery TE, Tran P.
Clin Adv Hematol Oncol. 2016 Mar;14(3 Suppl 3):11-3. PubMed PMID: 27007240.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SI, Ali SM.
Cancer Discov. 2016 Apr 5. PubMed PMID: 27048246.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.
Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA,Gitlitz B. 
Lung Cancer. 2015 May;88(2):231-4. doi:10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12. PubMed PMID: 25736571.

Pancytopenia in a patient with cystinosis secondary to myelosuppression from cystine crystal deposition: a case report.
Lyou Y, Zhao X, Nangia CS.
J Med Case Rep. 2015 Sep 17;9:205. doi: 10.1186/s13256-015-0691-8. PubMed PMID: 26377065; PubMed Central PMCID: PMC4573917.

Patients' preferences for biopsy result notification in an era of electronic messaging methods.
Choudhry A, Hong J, Chong K, Jiang B, Hartman R, Chu E, Nelson K, Wei ML, Nguyen T.
JAMA Dermatol. 2015 May;151(5):513-21. doi:10.1001/jamadermatol.2014.5634. PubMed PMID: 25831475.

Mammalian Y chromosomes retain widely expressed dosage-sensitive regulators.
Bellott DW, Hughes JF, Skaletsky H, Brown LG, Pyntikova T, Cho TJ, Koutseva N, Zaghlul S, Graves T, Rock S, Kremitzki C, Fulton RS, Dugan S, Ding Y, Morton D, Khan Z, Lewis L, Buhay C, Wang Q, Watt J, Holder M, Lee S, Nazareth L, Alföldi J,
Rozen S, Muzny DM, Warren WC, Gibbs RA, Wilson RK, Page DC.
Nature. 2014 Apr 24;508(7497):494-9. doi: 10.1038/nature13206. Erratum in: Nature. 2014 Oct 2;514(7520):126. PubMed PMID: 24759411; PubMed Central 
PMCID: PMC4139287.


The case of the missed physical examination: testicular carcinoma presenting as a GI bleed.
Kabir Y, Kleynberg RL, Rotblatt MD, Miller JM, Feldman NR.
JClin Oncol. 2013 Jul 10;31(20):e338-40. doi: 10.1200/JCO.2012.45.2680. Epub 2013 May 28. PubMed PMID: 23715583.

Mortality risk after preoperative versus postoperative chemotherapy and radiotherapy in lymph node-positive rectal cancer.
Seery TE, Ziogas A, Lin BS, Pan CJ, Stamos MJ, Zell JA.
J Gastrointest Surg. 2013 Feb;17(2):374-81. doi: 10.1007/s11605-012-2116-y. Epub 2012 Dec 14.PMID:23242847

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia.
Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, Li LS, Jessen KA, Martin MB, Ren P, Lilly MB, Sender LS, Liu Y, Rommel C, Fruman DA.
Leukemia. 2013 Mar;27(3):586-94. doi: 10.1038/leu.2012.276. Epub 2012 Oct 1. PMID:23090679

Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA.
Cancer. 2013 Jun 1;119(11):1969-75. doi: 10.1002/cncr.28040. Epub 2013 Mar 15. PMID:23505007

Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP, Zell JA, Rock CL, McLaren CE, Zoumas-Morse C, Gerner EW, Meyskens FL.
Br J Cancer. 2013 Feb 19;108(3):512-8. PMID:23340449

Excessive therapeutic response in a case of blastic plasmacytoid dendritic cell neoplasm.
Shieh MP, Reisian N, Walavalkar V, Slater LM, Lambrecht N.
Clin Adv Hematol Oncol. 2012 Jan;10(1):56-9. No abstract available. PMID:22398810

Population-based evaluation of adenosquamous carcinoma of the colon and rectum.
Masoomi H, Ziogas A, Lin BS, Barleben A, Mills S, Stamos MJ, Zell JA.
Dis Colon Rectum. 2012 May;55(5):509-14. PMID:22513428

Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy.
Soo RA, Kawaguchi T, Loh M, Ou SH, Shieh MP, Cho BC, Mok TS, Soong R.
Future Oncol. 2012 Apr;8(4):451-62. doi: 10.2217/fon.12.25. PMID:22515448

Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW, Meyskens FL.

New mechanistic explanation for the localization of ulcers in the rat duodenum: Role of iron and selective uptake of cysteamine.
Khomenko T, Kolodney J, Pinto JT, McLaren GD, Deng X, Chen L, Tolstanova G, Paunovic B, Krasnikov BF, Hoa N, Cooper AJ, Szabo S.
Arch Biochem Biophys. 2012 Sep 1;525(1):60-70. Epub 2012 Jun 7. PMID: 22684023

Meat consumption, ornithine decarboxylase gene polymorphism, and outcomes after colorectal cancer diagnosis. 
Zell JA, Lin BS, Ziogas A, Anton-Culver H.
J Carcinog. 2012;11:17. doi: 10.4103/1477-3163.104004. Epub 2012 Nov 28. PMID:23233821

Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis.
Raj KP, Taylor TH, Wray C, Stamos MJ, Zell JA.
J Carcinog. 2011 Mar 17;10:6.  PMID:21483654

Timing of radiation therapy, lymph node retrieval, and survival in rectal cancer.
Pan CJ, Ziogas A, Buchberg B, Raj KP, Mills SD, Stamos MJ, Zell JA.
Dis Colon Rectum. 2011 May;54(5):526-34.PMID:21471752

Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy. 
Shieh MP, Mehta RS.
Ann Oncol. 2011 Sep;22(9):2151-2. Epub 2011 Jul 28. No abstract available. PMID:21799203

Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.
Shieh MP, Mitsuhashi M, Lilly M.
Clin Med Insights Oncol. 2011;5:185-99. PMID: 21792346

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA.
Nat Med. 2010 Feb;16(2):205-13. Epub 2010 Jan 13. PMID: 20072130

Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. 
Nguyen AV, Albers CG, Holcombe RF.
Int J Mol Med. 2010 Jul;26(1):121-5. PMID: 20514431

Target of rapamycin signaling in leukemia and lymphoma.
Vu C, Fruman DA.
Clin Cancer Res. 2010 Nov 15;16(22):5374-80. Epub 2010 Sep 8. Review. PMID: 20826559

Program Administration »

Program Director:  Dr. Jason Zell
Division Chief:  Dr. Edward Nelson

Additional Key Clinical Faculty:
Dr. Elizabeth Brem
Dr. Rita Mehta
Dr. Viola Zhu

For more information, contact:

Elizabeth Yi, MPH, MBA
Division Adminisrator
Phone: 714-456-8100 or 714-456-5153
Fax: 714-456-2242
E-mail: elizabeth.yi@uci.edu


The Division of Hematology/Oncology
UC Irvine Medical Center
101 The City Drive South
Building 56, Room 239, ZOT 4061
Orange, CA 92868